EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance

Line A Mortensen, Claus Bistrup, Søren Rittig, Jens Michael Hertz, Kai M Schmidt-Ott, Enno Klussman, Christian Hinze, Boye L Jensen, Gitte R Hinrichs

Kidney International · 2026-09

DOI: 10.1016/j.kint.2026.08.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2026-09. Verfasst von Line A Mortensen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denma…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Forschung, Technologie und Raumfahrt, Region Syddanmark, Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Arginine vasopressin resistance (AVP-R), previously called nephrogenic diabetes insipidus, is a rare inherited disorder characterized by excessive urine output (often over 10 l/d) and a risk of life-threatening dehydration, resulting from kidney collecting duct insensitivity to arginine vasopressin. Currently, no curative treatment exists. Preclinical studies suggest that repurposing the antifungal fluconazole enhances AQP2-mediated water transport. Here, we present results from a clinical intervention study evaluating the effect of fluconazole on 24-hour urine output and urine concentrating ability in patients with congenital AVP-R caused by a pathogenic variant in the AVPR2 gene encoding the receptor of AVP. METHODS: We performed an open-label, nonrandomized intervention in five adult men with AVPR2-related AVP-R. Participants received oral fluconazole 400 mg daily for 14 days, with baseline and follow-up assessments including a water deprivation test. The primary endpoints were 24-hour urine output and urinary concentrating ability. Secondary endpoints included urinary and plasma osmolality, surrogate copeptin secretion, electrolytes, and micturition frequency. Safety and treatment adherence were evaluated weekly. RESULTS: Median fluconazole concentration after treatment was 13.7 μg/ml (range, 12.1-24.4 μg/ml) in plasma and 28.6 μg/ml (range, 22.4-34.7 μg/ml) in urine. Median change in 24-h urine output was +0.8 L (range, -3.6 to +5.7 L) and in urine osmolality -3 mOsm/kg (range, -78 to +25 mOsm/kg), with no change in micturition frequency. During water deprivation, body weight decreased by -2.0 to -2.8 kg at baseline vs. -2.1 to -3.1 kg after treatment, urine osmolality changed by -91 to +222 mOsm/kg vs. -12 to +193 mOsm/kg, and plasma copeptin increased by 4.8 to 16.8 pmol/l vs. 4.2 to 12.9 pmol/l. CONCLUSIONS: Fluconazole treatment did not reduce urine output or improve urine concentrating ability in adult patients with congenital AVP-R.

Schlagwörter

Stichwörter der Autor:innen

AVPR2antifungal agentsaquaporinsarginine vasopressinpolyuriavasopressin resistance

Autor:innen und Institutionen

  • Department of Nephrology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany; Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany.
  • Max-Delbrück-Centrum für Molekulare Medizin (MDC), Berlin, Germany; DZHK (German Centre for Cardiovascular Research), Berlin, Germany.
  • Department of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.

Förderung

  • Bundesministerium für Forschung, Technologie und Raumfahrt
  • Region Syddanmark
  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Mortensen, L. A., Bistrup, C., Rittig, S., Hertz, J. M., Schmidt-Ott, K. M., Klussman, E., Hinze, C., Jensen, B. L., & Hinrichs, G. R. (2026). Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance. Kidney International. https://doi.org/10.1016/j.kint.2026.08.024

Vancouver

Mortensen LA, Bistrup C, Rittig S, Hertz JM, Schmidt-Ott KM, Klussman E, et al. Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance. Kidney International. 2026. doi:10.1016/j.kint.2026.08.024

BibTeX
@article{Mortensen2026,
  author = {Mortensen, Line A and Bistrup, Claus and Rittig, Søren and Hertz, Jens Michael and Schmidt-Ott, Kai M and Klussman, Enno and Hinze, Christian and Jensen, Boye L and Hinrichs, Gitte R},
  title = {Impact of fluconazole in vasopressin 2 receptor-related congenital arginine vasopressin resistance},
  journal = {Kidney International},
  year = {2026},
  doi = {10.1016/j.kint.2026.08.024}
}
Kostenlos starten →